Pathios Therapeutics

Pathios Therapeutics is a clinical-stage oncology and immunology company based in Oxford, UK, focused on developing therapies that target the acid-sensing GPCR, GPR65. Their approach is unique and genetically-validated, aiming to revolutionize cancer treatment by addressing the root cause of dysfunctional immune cells within the acidic tumor microenvironment (TME). By inhibiting GPR65, Pathios aims to unlock the full potential of the immune system in fighting cancer, potentially benefiting a broad spectrum of cancer patients.

Pathios has made significant progress in developing their lead asset, PTT-4256, an orally-bioavailable, highly potent, and selective GPR65 inhibitor. They have raised over $58M in venture funding, including strategic investments from Bristol Myers Squibb, Canaan, and Brandon Capital. With a strong preclinical data package, Pathios is currently preparing to enter human clinical trials with PTT-4256, marking a significant milestone in their mission to deliver groundbreaking therapies for cancer.

Pathios Therapeutics is a clinical-stage oncology and immunology company focused on revolutionizing cancer treatment by targeting the acid-sensing GPCR, GPR65. They aim to transform cancer outcomes by addressing the underlying causal biology that links the acidic tumor microenvironment (TME) with detrimental immune cell function. Their unique, human genetics-led approach seeks to inhibit GPR65, a key driver of immunosuppressive immune cells within the TME, to unlock the immune system's full potential in fighting cancer.

Pathios Therapeutics promotes a culture of innovation and collaboration, drawing together experienced scientific leaders and drug discovery professionals to deliver new therapies in cancer. The company is based in Oxford, UK and is part of the M:M Bio (Molecule 2 Medicine) ecosystem, which provides operational and R&D support to help drug discovery companies achieve scientific, clinical, and commercial success. This collaborative environment fosters a spirit of teamwork and encourages the sharing of knowledge and expertise, which is essential for driving scientific breakthroughs in the field of oncology.